Improved influenza A virus vaccines using alpha-Gal epitope modification
使用 α-Gal 表位修饰改进甲型流感病毒疫苗
基本信息
- 批准号:7538785
- 负责人:
- 金额:$ 28.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-17 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylglucosamineAddressAdjuvantAnimalsAntibodiesAntibody FormationAntigen-Presenting CellsAntigensAreaBacteriaBiological Response Modifier TherapyCessation of lifeChemicalsClinical TrialsDevelopmentDiseaseDrug FormulationsEffectivenessElderlyEnsureEpitopesEstersFamilyFc ReceptorFlu virusGalactoseGenerationsGenesGeneticGenomeHealthHeatingHemagglutininHumanImmuneImmune responseImmunityIndividualInfectionInfluenzaInfluenza A virusInfluenza vaccinationInvestigationLeadLicensingLipidsMedicalModificationMovementNumbersOrganismOrthomyxoviridaeParasitesPersonsPharmacologic SubstancePhasePre-Clinical ModelPreparationProductivityProteinsPublic HealthRNAResearchRiskStandards of Weights and MeasuresSubunit VaccinesT-Lymphocyte SubsetsTechniquesTechnologyTestingTimeTransferaseUnited StatesVaccinatedVaccinationVaccine ProductionVaccinesViralViral VaccinesVirusVirus-like particleagedbasecancer immunotherapycell mediated immune responsecostcost effectivecytokinecytotoxicdesignhealth economicsimmunogenicityimmunosenescenceimprovedinfluenza virus vaccineinfluenzaviruskillingsmembernovelnovel vaccinesnovel viruspandemic diseasepathogenpreclinical studyresearch studyresponsesugarvaccine efficacy
项目摘要
DESCRIPTION (provided by applicant): Humans develop natural antibodies against a sugar molecule called Gal, which is present on proteins and lipids in most other species. These antibodies represent one of the strongest natural barriers to infection with bacteria, parasites and viruses. NewLink Genetics has licensed this technology as the HyperAcute(c) vaccine and it is in Phase I and II clinical trials as a cancer immunotherapy. In this application, we will use this antibody response as a natural biologic therapy to enhance influenza vaccine candidates. Influenza is a major human health threat and investigation of new vaccine strategies is a priority area of research. There are three specific aims in this proposal. (1) We will examine three different influenza vaccines (hemagglutinin protein, virus-like particles and heat-killed whole virus) with or without addition of the Gal epitopes to determine the vaccination efficacy of this molecule. (2) We will test three different strategies for adding the Gal molecule to a single vaccine in order to determine which modification strategy gives the best vaccine response. (3) We will test the hypothesis that use of Gal containing viral vaccines will enhance the immune response in a preclinical model of immunosenescence. These preclinical studies will be the first step in moving these experiments into a Phase II application where we will refine the best candidate vaccine in preparation for movement into clinical trials. PUBLIC HEALTH RELEVANCE: Influenza is a huge burden for the United States and the world, both in terms of human health and economic losses. The studies in this proposal focus on a novel adjuvant that will facilitate the development of more effective influenza vaccine formulations. We further propose that vaccines devloped with our adjuvant may also increase the immune response to influenza in the elderly.
描述(由申请人提供):人类产生针对称为Gal的糖分子的天然抗体,Gal存在于大多数其他物种的蛋白质和脂质中。这些抗体代表了细菌、寄生虫和病毒感染的最强天然屏障之一。NewLink Genetics已将该技术授权为HyperAcute(c)疫苗,目前正处于癌症免疫疗法的I期和II期临床试验中。在本申请中,我们将使用这种抗体反应作为天然生物疗法来增强流感疫苗候选物。流感是人类健康的主要威胁,研究新的疫苗策略是优先研究领域。这项建议有三个具体目标。(1)我们将研究三种不同的流感疫苗(血凝素蛋白,病毒样颗粒和热灭活的全病毒),添加或不添加Gal表位,以确定该分子的疫苗接种效果。(2)我们将测试将Gal分子添加到单一疫苗中的三种不同策略,以确定哪种修饰策略产生最佳疫苗应答。(3)我们将检验使用含半乳糖的病毒疫苗将增强免疫衰老的临床前模型中的免疫应答的假设。这些临床前研究将是将这些实验转入II期应用的第一步,在II期应用中,我们将改进最佳候选疫苗,为进入临床试验做准备。 公共卫生相关性:流感对美国和世界来说都是一个巨大的负担,无论是在人类健康还是经济损失方面。本提案中的研究重点是一种新的佐剂,这将有助于开发更有效的流感疫苗制剂。我们进一步提出,用我们的佐剂开发的疫苗也可能增加老年人对流感的免疫反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES J. LINK其他文献
CHARLES J. LINK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES J. LINK', 18)}}的其他基金
Improved influenza A virus vaccines using alpha-Gal epitope modification
使用 α-Gal 表位修饰改进甲型流感病毒疫苗
- 批准号:
7688152 - 财政年份:2008
- 资助金额:
$ 28.76万 - 项目类别:
VmatchNL - a user-friendly graphical interface for large-scale genome analysis
VmatchNL - 用于大规模基因组分析的用户友好图形界面
- 批准号:
7109734 - 财政年份:2006
- 资助金额:
$ 28.76万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Research Grant